GROUPE MACO PHARMA INTERNATIONAL - GMPI : revenue, balance sheet and financial ratios

GROUPE MACO PHARMA INTERNATIONAL - GMPI is a French company founded 16 years ago, specialized in the sector Activités des sièges sociaux. Based in TOURCOING (59200), this company of category ETI shows in 2024 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GROUPE MACO PHARMA INTERNATIONAL - GMPI (SIREN 512709080)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 1 594 647 € 1 603 200 € 1 652 262 € 2 554 588 € 560 087 € N/C N/C N/C N/C
Net income 5 230 747 € -2 115 204 € 6 834 830 € 6 375 341 € 307 189 € -38 668 667 € 51 442 € 307 891 € -8 109 153 €
EBITDA -2 252 779 € -1 553 615 € -1 339 253 € -1 535 247 € -1 021 030 € -1 486 900 € -1 535 562 € -717 859 € -557 771 €
Net margin 328.0% -131.9% 413.7% 249.6% 54.8% N/C N/C N/C N/C

Revenue and income statement

In 2024, GROUPE MACO PHARMA INTERNATIONAL - GMPI achieves revenue of 1.6 M€. Over the period 2020-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +29.9%. Slight decline of -1% vs 2023. After deducting consumption (0 €), gross margin stands at 1.6 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -2.3 M€, representing -141.3% of revenue. Warning negative scissor effect: despite revenue change (-1%), EBITDA varies by -45%, reducing margin by 44.4 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 5.2 M€, i.e. 328.0% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

1 594 647 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

1 594 647 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-2 252 779 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-1 558 067 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

5 230 747 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-141.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 197.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

78.883%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

197.577%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
GROUPE MACO PHARMA INTERNATIONAL - GMPI

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.06
Med: 14.61
Q3: 89.57
Excellent

In 2024, the debt ratio of GROUPE MACO PHARMA INTERN... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
78.88% 2024
2022
2023
2024
Q1: 11.57%
Med: 51.97%
Q3: 85.24%
Good

In 2024, the financial autonomy of GROUPE MACO PHARMA INTERN... (78.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.2 years
Q3: 3.73 years
Excellent -15 pts over 3 years

In 2024, the repayment capacity of GROUPE MACO PHARMA INTERN... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 172.29. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

172.288

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-184.626

Liquidity indicators evolution
GROUPE MACO PHARMA INTERNATIONAL - GMPI

Sector positioning

Liquidity ratio
172.29 2024
2022
2023
2024
Q1: 116.63
Med: 458.65
Q3: 2184.57
Average

In 2024, the liquidity ratio of GROUPE MACO PHARMA INTERN... (172.29) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-184.63x 2024
2022
2023
2024
Q1: -45.56x
Med: 0.0x
Q3: 2.85x
Average

In 2024, the interest coverage of GROUPE MACO PHARMA INTERN... (-184.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 6 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 50 days. Excellent situation: suppliers finance 44 days of the operating cycle (retail model). WCR is negative (-56 days): operations structurally generate cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-246 485 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

6 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

50 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-56 j

WCR and payment terms evolution
GROUPE MACO PHARMA INTERNATIONAL - GMPI

Positioning of GROUPE MACO PHARMA INTERNATIONAL - GMPI in its sector

Comparison with sector Activités des sièges sociaux

Valuation estimate

Based on 103 transactions of similar company sales in 2024, the value of GROUPE MACO PHARMA INTERNATIONAL - GMPI is estimated at 20 254 708 € (range 7 002 872€ - 54 296 416€). The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
103 transactions
7002k€ 20254k€ 54296k€
20 254 708 € Range: 7 002 872€ - 54 296 416€
NAF 5 année 2024

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
1 594 647 € × 0.38x
Estimation 602 167 €
287 011€ - 1 216 170€
Net Income Multiple 20%
5 230 747 € × 9.5x
Estimation 49 733 520 €
17 076 664€ - 133 916 787€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sièges sociaux)

Compare GROUPE MACO PHARMA INTERNATIONAL - GMPI with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sièges sociaux

Frequently asked questions about GROUPE MACO PHARMA INTERNATIONAL - GMPI

What is the revenue of GROUPE MACO PHARMA INTERNATIONAL - GMPI ?

The revenue of GROUPE MACO PHARMA INTERNATIONAL - GMPI in 2024 is 1.6 M€.

Is GROUPE MACO PHARMA INTERNATIONAL - GMPI profitable?

Yes, GROUPE MACO PHARMA INTERNATIONAL - GMPI generated a net profit of 5.2 M€ in 2024.

Where is the headquarters of GROUPE MACO PHARMA INTERNATIONAL - GMPI ?

The headquarters of GROUPE MACO PHARMA INTERNATIONAL - GMPI is located in TOURCOING (59200), in the department Nord.

Where to find the tax return of GROUPE MACO PHARMA INTERNATIONAL - GMPI ?

The tax return of GROUPE MACO PHARMA INTERNATIONAL - GMPI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GROUPE MACO PHARMA INTERNATIONAL - GMPI operate?

GROUPE MACO PHARMA INTERNATIONAL - GMPI operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.